Last checked at 
BERLIN, Jan 25 (Reuters) - Germany expects to receive 3.8
million doses of Novavax's newly approved COVID-19
vaccine Nuvaxovid by March 20, the health ministry said on
Tuesday, as the government looks to persuade unvaccinated
Germans to get a shot.
Germany will receive 1.4 million doses in the week of Feb.
21 and should receive the rest of the 3.8 million doses in the
subsequent few weeks.
Novavax is expected to deliver 34 million doses to Germany
this year. The shipment is a part of the U.S. drugmaker's deal
to supply up to 200 million doses to the European Union's 27
member states.
Novavax's protein-based vaccine, which was approved by the
European Medicines Agency (EMA) in December, uses alternative
technology to the vaccines from Pfizer-BioNTech,
, Moderna, AstraZeneca and J&J
.
This could convince reluctant Germans, sceptical about the
novel mRNA technology and its long-term effects, to take
Novavax's more traditional vaccine and boost Germany's
vaccination rate, which is lower than other western European
countries.
Data from two large studies showed the vaccine has an
efficacy rate of around 90% and the firm said early data showed
it was effective in generating an immune response against the
more infectious Omicron variant.
(Reporting by Riham Alkousaa and Andreas Rinke; editing by
Jason Neely)
